SCHEMBL3783753

SCHEMBL3783753

O=C1NCCN1c1cnc2ccccc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.53
CHRNA4 P43681 1/20 0.53
HTR3A P46098 1/20 0.51
HDAC1 Q13547 1/20 0.51
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
DHFR P00374 1/20 0.47
AKR1C3 P42330 1/20 0.45
NISCH Q9Y2I1 1/20 0.43
PARP10 Q53GL7 1/20 0.41
PARP11 Q9NR21 1/20 0.41
EGLN1 Q9GZT9 1/20 0.40
CYP1A2 P05177 1/20 0.40
CNR2 P34972 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
MGAM O43451 1/20 0.40
HTR6 P50406 1/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3781533 0.82 POLB (0.50) HDAC1KDM4ENPC1TP53RAB9A
SCHEMBL9645648 0.79 ALOX5 (0.57) CHRNB2CHRNA4HTR3A
SCHEMBL29433019 0.77 GRM5 (0.48) CHRNB2CHRNA4HTR3AHDAC1CYP11B1
SCHEMBL5604821 0.77 HTR6 (0.56) CHRNB2CHRNA4HTR3AHDAC1CYP11B1
SCHEMBL3782634 0.76 SLC6A2 (0.54) HTR3ACYP11B1CYP11B2CYP1A2ALDH1A1
SCHEMBL8567898 0.75 HDAC1 (0.50) CHRNB2CHRNA4HTR3AHDAC1CYP11B1
SCHEMBL15297098 0.74 HTR6 (0.51) CHRNB2CHRNA4HTR3AHDAC1CYP11B1
SCHEMBL13837667 0.74 HDAC1 (0.49) CHRNB2CHRNA4HTR3AHDAC1CYP11B1
SCHEMBL4355823 0.74 CHRNB2 (0.89) CHRNB2CHRNA4HTR3ACYP11B1CYP11B2
SCHEMBL30020071 0.74 CHRNB2 (0.89) CHRNB2CHRNA4HTR3ACYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45173-E1 Inhibitors of CYP 17 NOVARTIS AG (CH) 2014-09-30 US disclosed
US-20140228394-A1 INHIBITORS OF CYP 17 NOVARTIS AG (CH) 2014-08-14 US disclosed
US-8263635-B2 Inhibitors of CYP 17 NOVARTIS AG (CH) 2012-09-11 US disclosed
US-20100331326-A1 Inhibitors of CYP 17 NOVARTIS AG 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331326-A1 Inhibitors of CYP 17 CYP17A1, CYP21A2, CYP4A22 CHRNB2 2702/4885CHRNA4 1820/4885HTR3A 710/4885
US-20140228394-A1 INHIBITORS OF CYP 17 CYP17A1, CYP21A2, CYP4A22 CHRNB2 2702/4885CHRNA4 1820/4885HTR3A 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.